Aberrant expression of miR‑4728 in patients with non‑small cell lung cancer and its regulatory effects on tumor progression in tumor cells

Hu,Ying; Zhang,Xinfang; Gong,Cuixue; Li,Jianzhao

doi:10.3892/etm.2020.9141

Aberrant expression of miR‑4728 in patients with non‑small cell lung cancer and its regulatory effects on tumor progression in tumor cells

Authors:
- Ying Hu
- Xinfang Zhang
- Cuixue Gong
- Jianzhao Li
View Affiliations

Affiliations: Department of Blood Transfusion, Qilu Hospital Huantai Branch, Zibo, Shandong 256400, P.R. China, Clinical Laboratory, Qilu Hospital Huantai Branch, Zibo, Shandong 256400, P.R. China, Outpatient Dressing Room, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China, Department of Pathology, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China
Published online on: August 26, 2020 https://doi.org/10.3892/etm.2020.9141
Article Number: 15
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is a common malignant tumor with poor prognosis and an increasing number of cases. MicroRNA (miR)‑4728 is related with the progression of various types of cancer, and is dysregulated in NSCLC, which indicates that miR‑4728 may serve as a biomarker for NSCLC. The present study aimed to investigate the clinical significance of miR‑4728 in NSCLC diagnosis and prognosis, and to explore the biological function of miR‑4728 in NSCLC progression. Serum and tissue samples were collected from 122 patients with NSCLC. By conducting reverse transcription‑quantitative PCR, the Cell Counting Kit‑8 assay and Transwell assays, the expression of miR‑4728 and its effect on NSCLC cell proliferation, migration and invasion were investigated. The diagnostic value of miR‑4728 was evaluated by plotting a receiver operating characteristic curve, and Kaplan‑Meier and Cox regression analyses were conducted to assess the prognostic value of miR‑4728. miR‑4728 was significantly downregulated in NSCLC serum and tissue samples compared with healthy controls, with a relatively high diagnostic accuracy and ability to predict poor overall survival time in patients with NSCLC. By conducting gain‑ and loss‑of‑function experiments, the results indicated that miR‑4728 knockdown significantly promoted NSCLC cell proliferation, migration and invasion compared with the inhibitor negative control (NC) group. By contrast, miR‑4728 overexpression displayed the opposite effect on NSCLC cell proliferation, migration and invasion. The present study indicated that miR‑4728 was downregulated in NSCLC and may serve as a candidate diagnostic and prognostic biomarker. NSCLC cell proliferation, migration and invasion were inhibited by miR‑4728 overexpression compared with the mimic NC group, which suggested that miR‑4728 may serve as a therapeutic target for NSCLC.

View Figures

View References

1	Nasim F, Sabath BF and Eapen GA: Lung cancer. Med Clin North Am. 103:463–473. 2019.PubMed/NCBI View Article : Google Scholar
2	Mao Y, Yang D, He J and Krasna MJ: Epidemiology of lung cancer. Surg Oncol Clin N Am. 25:439–445. 2016.PubMed/NCBI View Article : Google Scholar
3	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008.PubMed/NCBI View Article : Google Scholar
4	Dimitrakopoulos FD, Antonacopoulou AG, Kottorou AE, Maroussi S, Panagopoulos N, Koukourikou I, Scopa C, Kalofonou M, Koutras A, Makatsoris T, et al: NF-kB2 genetic variations are significantly associated with non-small cell lung cancer risk and overall survival. Sci Rep. 8(5259)2018.PubMed/NCBI View Article : Google Scholar
5	Feng S, Zhai J, Lu D, Lin J, Dong X, Liu X, Wu H, Roden AC, Brandi G, Tavolari S, et al: TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells. Exp Cell Res. 373:44–56. 2018.PubMed/NCBI View Article : Google Scholar
6	Sahin S, Batur S, Aydin O, Ozturk T, Turna A and Oz B: Programmed death-ligand-1 expression in non-small cell lung cancer and prognosis. Balkan Med J. 36:184–189. 2019.PubMed/NCBI View Article : Google Scholar
7	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014.PubMed/NCBI View Article : Google Scholar
8	Wu KL, Tsai YM, Lien CT, Kuo PL and Hung AJ: The roles of MicroRNA in lung cancer. Int J Mol Sci. 20(1611)2019.PubMed/NCBI View Article : Google Scholar
9	Liu S, Yang Y, Jiang S, Tang N, Tian J, Ponnusamy M, Tariq MA, Lian Z, Xin H and Yu T: Understanding the role of non-coding RNA (ncRNA) in stent restenosis. Atherosclerosis. 272:153–161. 2018.PubMed/NCBI View Article : Google Scholar
10	Palomer X, Pizarro-Delgado J and Vazquez-Carrera M: Emerging actors in diabetic cardiomyopathy: Heartbreaker biomarkers or therapeutic targets? Trends Pharmacol Sci. 39:452–467. 2018.PubMed/NCBI View Article : Google Scholar
11	Wang J, Liu H and Li M: Downregulation of miR-505 promotes cell proliferation, migration and invasion, and predicts poor prognosis in breast cancer. Oncol Lett. 18:247–254. 2019.PubMed/NCBI View Article : Google Scholar
12	Zhang S, Zhang R, Xu R, Shang J, He H and Yang Q: MicroRNA-574-5p in gastric cancer cells promotes angiogenesis by targeting protein tyrosine phosphatase non-receptor type 3 (PTPN3). Gene. 733(144383)2020.PubMed/NCBI View Article : Google Scholar
13	Vosa U, Vooder T, Kolde R, Fischer K, Valk K, Tonisson N, Roosipuu R, Vilo J, Metspalu A and Annilo T: Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes Chromosomes Cancer. 50:812–822. 2011.PubMed/NCBI View Article : Google Scholar
14	Cai K, Li HX, Li PP, Guo ZJ and Yang Y: MicroRNA-449b-3p inhibits epithelial-mesenchymal transition by targeting IL-6 and through the JAK2/STAT3 signaling pathway in non-small cell lung cancer. Exp Ther Med. 19:2527–2534. 2020.PubMed/NCBI View Article : Google Scholar
15	Cai T, Long J, Wang H, Liu W and Zhang Y: Identification and characterization of miR-96, a potential biomarker of NSCLC, through bioinformatic analysis. Oncol Rep. 38:1213–1223. 2017.PubMed/NCBI View Article : Google Scholar
16	Zhu J, Zeng Y, Xu C, Qin H, Lei Z, Shen D, Liu Z and Huang JA: Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer. Oncol Rep. 34:1779–1786. 2015.PubMed/NCBI View Article : Google Scholar
17	Liu Z, Zhang J, Gao J and Li Y: MicroRNA-4728 mediated regulation of MAPK oncogenic signaling in papillary thyroid carcinoma. Saudi J Biol Sci. 25:986–990. 2018.PubMed/NCBI View Article : Google Scholar
18	Li H, Zhou X, Zhu J, Cheng W, Zhu W, Shu Y and Liu P: MiR-4728-3p could act as a marker of HER2 status. Cancer Biomark. 15:807–814. 2015.PubMed/NCBI View Article : Google Scholar
19	Osmani L, Askin F, Gabrielson E and Li QK: Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 52:103–109. 2018.PubMed/NCBI View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
21	Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et al: Staging system for breast cancer: Revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin North Am. 83:803–819. 2003.PubMed/NCBI View Article : Google Scholar
22	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018.PubMed/NCBI View Article : Google Scholar
23	Hall RD, Gray JE and Chiappori AA: Beyond the standard of care: A review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control. 20:22–31. 2013.PubMed/NCBI View Article : Google Scholar
24	Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, Bergstrom S, Hanna L, Jakobsen E, Kölbeck K, et al: Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: A population-based study, 2004-2007. Thorax. 68:551–564. 2013.PubMed/NCBI View Article : Google Scholar
25	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
26	Wei F, Wang M, Li Z, Wang Y and Zhou Y: MiR593 inhibits proliferation and invasion and promotes apoptosis in non-small cell lung cancer cells by targeting SLUG-associated signaling pathways. Mol Med Rep. 20:5172–5182. 2019.PubMed/NCBI View Article : Google Scholar
27	Yang D, Li JS, Xu QY, Xia T and Xia JH: Inhibitory Effect of MiR-449b on cancer cell growth and invasion through LGR4 in non-small-cell lung carcinoma. Curr Med Sci. 38:582–589. 2018.PubMed/NCBI View Article : Google Scholar
28	Tang X, Ding Y, Wang X, Zhao L and Bi H: MiR-650 promotes non-small cell lung cancer cell proliferation and invasion by targeting ING4 through Wnt-1/β-catenin pathway. Oncol Lett. 18:4621–4628. 2019.PubMed/NCBI View Article : Google Scholar
29	He S, Liao B, Deng Y, Su C, Tuo J, Liu J, Yao S and Xu L: MiR-216b inhibits cell proliferation by targeting FOXM1 in cervical cancer cells and is associated with better prognosis. BMC Cancer. 17(673)2017.PubMed/NCBI View Article : Google Scholar
30	Bi CW, Zhang GY, Bai Y, Zhao B and Yang H: Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer. Medicine (Baltimore). 98(e16705)2019.PubMed/NCBI View Article : Google Scholar
31	Schmitt DC, Madeira da Silva L, Zhang W, Liu Z, Arora R, Lim S, Schuler AM, McClellan S, Andrews JF, Kahn AG, et al: ErbB2-intronic microRNA-4728: A novel tumor suppressor and antagonist of oncogenic MAPK signaling. Cell Death Dis. 6(e1742)2015.PubMed/NCBI View Article : Google Scholar
32	Newie I, Sokilde R, Persson H, Grabau D, Rego N, Kvist A, von Stedingk K, Axelson H, Borg A, Vallon-Christersson J and Rovira C: The HER2-encoded miR-4728-3p regulates ESR1 through a non-canonical internal seed interaction. PLoS One. 9(e97200)2014.PubMed/NCBI View Article : Google Scholar